CompletedNot Applicable

Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)

France10 participantsStarted 2019-03-06

Plain-language summary

This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy for bronchial cancer. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 and over. * with bronchial cancer treated with immunotherapy, * having two assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response) * without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy * eligible for a home-based hospitalization Exclusion Criteria: * Patient receiving immunotherapy via temporary authorization for use, * Frail patients requiring a frequent medical assessment thus day hospitalization cares

What they're measuring

Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)

Timeframe: 1 year

Trial details

NCT IDNCT03786653

SponsorRENAULT Patrick Aldo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-06

View on ClinicalTrials.gov More Bronchial Cancer trials